{
    "nctId": "NCT00705315",
    "briefTitle": "Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer",
    "officialTitle": "Docetaxel-epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 Negative Breast Cancer. A Multicenter Phase I-II Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Overall Response Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically- or cytologically- confirmed metastatic breast adenocarcinoma\n* No HER2 overexpression or gene amplification\n* No previous therapy for metastatic breast cancer is allowed\n* Age 18-75 years\n* At least 12 months interval since prior adjuvant therapy with taxanes and/or anthracyclines\n* Measurable disease as defined by the presence of at least one measurable lesion (except bone metastases, ascites or pleural effusions)\n* Performance status (WHO) 0-2\n* Adequate liver (serum bilirubin \\<1.5 times the upper normal limit, AST and ALT \\<2.5 times the upper normal limit in the absence of demonstrable liver metastases, or \\<5 times the UNL in the presence of liver metastases)\n* Adequate renal function (serum creatinine \\<1.5 times the upper normal limit\n* Adequate bone marrow function (neutrophils \u2265 1.5x 109 /L, and platelets \u2265 100x 109 /L)\n* Written informed consent\n\nExclusion Criteria:\n\n* Active infection\n* Brain metastases\n* History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias)\n* History of stroke\n* Anticoagulation therapy (except of low dose aspirin \\<325mg)\n* Other invasive malignancy except nonmelanoma skin cancer\n* Psychiatric illness or social situation that would preclude study compliance\n* Pregnant or lactating women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}